Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
Editor's Choice
LIPID DISORDERS / RESEARCH LETTER
Association between Lp(a) and T2D: a Mendelian randomization study
1
Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
2
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
3
Ciccarone Center for the Prevention of Cardiovascular Disease, School of Medicine, Johns Hopkins University, United States
4
Department of Family Medicine and Public Health, University of Opole, Poland
5
Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Poland
Submission date: 2024-04-09
Final revision date: 2024-04-19
Acceptance date: 2024-04-20
Online publication date: 2024-04-20
Corresponding author
Mateusz Lejawa
Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
Arch Med Sci 2024;20(3):1002-1005
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Blood lipoprotein(a) (Lp(a)) levels have been observed to be inversely correlated with type 2 diabetes (T2D). In this Mendelian randomization (MR) study, the causal impact of genetically predicted Lp(a) on T2D was assessed.
Methods:
A two-sample MR analysis was conducted. Data were obtained from UK Biobank and FinnGen consortia. Primary analysis was based on an inverse-variance-weighted mean (IVM) approach.
Results:
No statistically significant association between the genetically predicted levels of Lp(a) and T2D was detected (p = 0.362) in IVM analysis involving data of 563,420 patients.
Conclusions:
Genetically predicted Lp(a) concentration does not appear to be causally related to the risk of T2D.
Blood lipoprotein(a) (Lp(a)) levels have been observed to be inversely correlated with type 2 diabetes (T2D). In this Mendelian randomization (MR) study, the causal impact of genetically predicted Lp(a) on T2D was assessed.
Methods:
A two-sample MR analysis was conducted. Data were obtained from UK Biobank and FinnGen consortia. Primary analysis was based on an inverse-variance-weighted mean (IVM) approach.
Results:
No statistically significant association between the genetically predicted levels of Lp(a) and T2D was detected (p = 0.362) in IVM analysis involving data of 563,420 patients.
Conclusions:
Genetically predicted Lp(a) concentration does not appear to be causally related to the risk of T2D.
REFERENCES (21)
1.
Cybulska B, Kłosiewicz-Latoszek L, Penson PE. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? Prog Cardiovasc Dis 2020; 63: 219-27.
2.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
3.
Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res 2016; 57: 745-57.
4.
Skoumas I, Andrikou I, Grigoriou K, et al. Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: a 9 year follow-up study. J Clin Lipidol 2023; 17: 512-8.
5.
Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis 2022; 349: 63-71.
6.
Burgess S, Thompson SG. Mendelian Randomization: Methods for Causal Inference Using Genetic Variants. Second edition. CRC Press 2021.
7.
GWAS of UK Biobank biomarker measurements. Neale lab. Published September 16, 2019. Accessed March 30, 2024. http://www.nealelab.is/blog/20....
8.
Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023; 613: 508-18.
10.
Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 2017; 36: 1783-802.
11.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-46.
12.
Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology 2017; 28: 30-42.
13.
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
14.
Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017; 46: 1985-98.
15.
Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 2015; 34: 2926-40.
16.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
17.
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50: 693-8.
18.
Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 1999; 42: 41-4.
19.
Buchmann N, Scholz M, Lill CM, et al. Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetol 2017; 54: 1031-8.
20.
Sosnowska B, Surma S. Targeted treatment against lipoprotein (a): The coming breakthrough in lipid lowering therapy. Pharmaceuticals 2022; 15: 1573.
21.
Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP). 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci 2023; 19: 1602-15.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
